The Carbamazepine market has experienced a price rebound in India this April after several months of declining prices. This marks a turnaround for suppliers and buyers who had been facing continuous price drops since late xxxx. The price jump has also had a ripple effect on the U.S. market as India is a key supplier of Carbamazepine to American pharmaceutical companies. The sudden price shift comes after months of weak demand and high stock levels. The market has seen a recovery as demand for Carbamazepine surged in certain sectors which triggered a rise in prices.
Carbamazepine prices were declining throughout late xxxx and into early xxxx. The primary reason for the price drop was low demand from major sectors such as neurology and psychiatric care, alongside large inventories held by distributors. The high stock levels kept prices at lower end as...
